PDCD1 and neoplasm: Another study demonstrated the potential clinical benefit of incorporating the PD-L1/PD-1 checkpoint blockade into radiotherapy regimens to sensitize tumor cells to NK cell-mediated killing in nasopharyngeal carcinoma [144].